Andere Sprachen X4 Pharmaceuticals, Inc.

Aktien

A2PFVY

US98420X1037

XFOR

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 22.04.2024			% 5 Tage	% 1. Jan.
1.36 ^USD	+7.94%		+8.80%	+62.19%

21.03.	Transcript : X4 Pharmaceuticals, Inc., Q4 2023 Earnings Call, Mar 21, 2024
21.03.	X4 Pharmaceuticals, Inc. meldet Ergebnis für das vierte Quartal und das Gesamtjahr bis zum 31. Dezember 2023	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)	03.04.
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	02.04.
X4 Pharmaceuticals : Regulation FD Disclosure - Form 8-K	01.04.
X4 Pharmaceuticals to Participate in Upcoming April Investor Conferences	01.04.
X4 Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	21.03.
X4 Pharmaceuticals: Q4 Earnings Snapshot	21.03.
North American Morning Briefing : Investors -2-	21.03.
X4 Pharmaceuticals Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides Corporate Update	21.03.
X4 Pharmaceuticals to Report Fourth-Quarter and Full Year 2023 Financial Results and Host a Conference Call and Webcast on March 21, 2024	12.03.
Thinking about buying stock in Marpai, Axcelis Technologies, Amylyx Pharmaceuticals, Biomx, or X4 Pharmaceuticals?	11.03.
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)	04.03.
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	01.03.
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	01.02.
North American Morning Briefing : Traders Await -2-	13.12.
X4 Pharmaceuticals Announces Presentation of Additional Data from Mavorixafor Phase 2 Trial in Chronic Neutropenia at ASH 2023	11.12.
X4 Pharmaceuticals Announces Presentation of Additional Data from Mavorixafor Phase 2 Trial in Chronic Neutropenia at ASH 2023	09.12.
X4 Pharmaceuticals, Inc. Announces Presentation of Additional Data from Mavorixafor Phase 2 Trial in Chronic Neutropenia at ASH 2023	09.12.
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)	05.12.
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	04.12.
X4 Pharmaceuticals to Participate in Upcoming November Investor Conferences	10.11.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen X4 Pharmaceuticals, Inc.

Aktien

A2PFVY

US98420X1037

XFOR

Andere Sprachen

Filter